Menu Back to Advertising-and-Promotion-Regulatory-and-Affairs-Meeting

Overview

Designed by Advertising and Promotion professionals for Advertising and Promotion professionals – as well as their legal, marketing, and consulting colleagues -- DIA’s Advertising and Promotion Regulatory Affairs Conference offers a comprehensive agenda for beginners to the field as well as the most experienced. The conference, which has taken place annually for 30 years, delivers a multi-stakeholder perspective on new FDA guidances and the latest enforcement, the challenges of marketing pharmaceuticals and medical devices in a mobile-first world, and new technologies relevant to the promotion of FDA-regulated products. Industry and government thought leaders will facilitate interactive, forward-looking discussions that will shape policy, advance understanding, and define strategic priorities within the ad promo regulatory space.

Program Update! FDA publishes 2 final guidances that provide greater clarity about their thinking and recommendations for certain medical product communications. Register to learn how these are being incorporated into the 2019 program.



Content Preview Webinar

Navigating Key FDA Advertising and Promotion Developments in a New Year | January 29 | 12:30PM-1:30PM ET
As a prelude to DIA’s Advertising and Promotion Regulatory Affairs Conference, this webinar, will begin with a brief year in review of the latest regulatory activities in this space, followed by a deeper dive into emerging regulations and policies for DTC communications.
Register today.

Who should attend?

Professionals in pharmaceutical, biologics, and medical device companies involved in:

  • Regulatory Affairs
  • Marketing
  • Communications
  • Compliance
  • Medical Information and Affairs
  • Legal
  • Senior Management

Learning objectives

At the end of this conference participants should be able to:

  • Discuss the latest FDA policies, guidances and how they apply on a practical basis to day to day oversight of ad promo materials for pharmaceuticals, biological products and medical devices
  • Describe how other companies are interpreting policies and applying them to the current marketplace
  • Recognize the latest policies and emerging regulations with regard to direct to consumer promotion and advertising
  • Apply the latest policies to better communicate with all audiences, including payer discussions
  • Select and implement effective digital and social media strategies to meet the challenges of ensuring compliance with FDA regulatory requirements

    Program Committee

    • Micheline  Awad, MBA
      Micheline Awad, MBA Director Regulatory Affairs, Advertising and Promotion
      Neurocrine Biosciences, Inc., United States
    • Glenn N. Byrd, MBA, RAC
      Glenn N. Byrd, MBA, RAC Senior Director, Oncology Promotional Regulatory Affairs
      AstraZeneca, United States
    • Dale  Cooke, MA
      Dale Cooke, MA President
      PhillyCooke Consulting , United States
    • Mark  Gaydos
      Mark Gaydos VP, NA General Medicines/US Advertising and Promotion, Global Regulatory Affairs
      Sanofi, United States
    • Sheetal  Patel, PharmD
      Sheetal Patel, PharmD Head, Regulatory Advertising and Promotion
      Johnson & Johnson International, United States
    • Michele  Sharp, PharmD
      Michele Sharp, PharmD Senior Director, Global Regulatory Affairs
      Eli Lilly and Company, United States
    • Thomas W. Abrams, MBA
      Thomas W. Abrams, MBA Director, Office of Prescription Drug Promotion, OMP, CDER
      FDA, United States
    • Wayne L. Pines
      Wayne L. Pines President, Regulatory Services and Healthcare
      APCO Worldwide Inc., United States
    • Lucy  Rose, MBA
      Lucy Rose, MBA President
      Lucy Rose and Associates, LLC, United States
    Load More